Biocon, Pfizer enter global contract to commercialize Insulin analog products Biocon, Asia’s premier biotechnology firm, and Pfizer Inc click here . Biocon will remain in charge of the clinical development, supply and manufacture of the biosimilar Insulin products, as well for regulatory actions to secure authorization for the products in a variety of geographies.

THE BUSINESS has planned a pre-NDA meeting to attain agreement on a comprehensive NDA submission. BioCryst will announce its upcoming plans beneath the peramivir advanced advancement agreement upon receiving formal assistance from Biomedical Advanced Analysis and Advancement Authority after its recently finished In-Procedure Review. In March, BioCryst initiated a Stage 1 scientific trial with BCX4161 to aid its development as cure for hereditary angioedema . The primary objectives of the Stage 1 scientific trial are to show safety, consistent and sufficient drug exposure, and pharmacodynamic results after oral administration. Furthermore, BioCryst has identified many second era oral HAE compounds, and plans to choose a lead applicant for preclinical development afterwards in 2013.